Tmunity Therapeutics, Inc., a Philadelphia, PA-based clinical-stage biotherapeutics company, closed a $100m Series A financing.
Backers included Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences, Be The Match BioTherapies, and seed investors the University of Pennsylvania and Lilly Asia Ventures.
The proceeds will be used to advance and expand the business and operational structure of Tmunity to support the rapid translation, development and manufacture of its portfolio of novel T cell based immunotherapies, first for the treatment of cancer.
Led by Usman “Oz” Azam, M.D., President and Chief Executive Officer, Tmunity is developing a diversified portfolio of novel treatments that exhibit control over T cell activation and direction in the body. These personalized immunotherapies for cancer, infectious disease and autoimmune disease are now advancing toward the clinic.
The company was founded on an exclusive collaboration and license agreement with the University of Pennsylvania, offering proprietary technologies and expertise in first-in-patient cell and gene therapies of its scientific founders, led by Carl H. June, M.D.
Tmunity utilizes laboratories and production facilities at UPenn and its own dedicated cGMP manufacturing facility in Norristown, PA.